15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Opioid–galanin receptor heteromers differentiate the dopaminergic effects of morphine and methadone

      article-commentary
      ,
      The Journal of Clinical Investigation
      American Society for Clinical Investigation

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          As the opioid addiction crisis reaches epidemic levels, the identification of opioid analgesics that lack abuse potential may provide a path to safer treatment of chronic pain. Preclinical studies have demonstrated that galanin affects physical dependence and rewarding actions associated with morphine. In the brain and periphery, galanin and opioids signal through their respective GPCRs, GalR1–3 and the μ-opioid receptor (MOR). In this issue of the JCI, Cai and collaborators reveal that heteromers between GalR1 and MOR in the rat ventral tegmental area attenuate the potency of methadone, but not other opioids, in stimulating the dopamine release that produces euphoria. These studies help us understand why some synthetic opioids, such as methadone, do not trigger the release of dopamine in the mesolimbic system but still possess strong analgesic properties.

          Related collections

          Author and article information

          Contributors
          Journal
          J Clin Invest
          J. Clin. Invest
          J Clin Invest
          The Journal of Clinical Investigation
          American Society for Clinical Investigation
          0021-9738
          1558-8238
          28 May 2019
          28 May 2019
          1 July 2019
          1 July 2020
          : 129
          : 7
          : 2653-2654
          Affiliations
          Nash Family Department of Neuroscience and Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
          Author notes
          Address correspondence to: Venetia Zachariou, 1425 Madison Ave, Box 10-65, New York, New York 10029, USA. Phone: 212.659.8612; Email: venetia.zachariou@ 123456mssm.edu .
          Author information
          http://orcid.org/0000-0002-5836-3686
          Article
          PMC6597226 PMC6597226 6597226 128987
          10.1172/JCI128987
          6597226
          31135380
          fcaf4884-2c74-4b30-b18f-f22e32e42d26
          © 2019 American Society for Clinical Investigation
          History
          Categories
          Commentary

          Comments

          Comment on this article